PLx Pharma Inc. to Discuss 2021 Third Quarter Financial Results on November 12, 2021 Conference Call and Provide Business Update
November 01 2021 - 3:30PM
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a
specialty pharmaceutical company focused on its
clinically-validated and patent-protected PLxGuard™ drug delivery
platform that has the potential to improve the absorption of many
drugs currently on the market and to reduce the risk of stomach
injury associated with certain drugs. The Company, with its lead
products VAZALORE™ 325 mg and VAZALORE™ 81 mg liquid-filled aspirin
capsules (referred to together as “VAZALORE”), announced today that
it will release 2021 third quarter financial results on Friday,
November 12, 2021, before the U.S. financial markets open.
Natasha Giordano, President and Chief Executive Officer, and
Rita O’Connor, Chief Financial Officer, will host a conference call
to discuss the results and provide a business update as
follows:
Date |
Friday, November 12, 2021 |
Time |
8:30 a.m. ET |
Toll free (U.S.) |
(866) 394-2901 |
InternationalConference ID |
(616) 548-55673045127 |
Webcast (live and replay) |
www.plxpharma.com under the
‘Investor Relations’ section. |
A replay of the conference call will be available for two weeks
after the call's completion by dialing (855) 859-2056 (U.S.) or
(404) 537-3406 (International). The conference ID for the replay is
3045127. The archived webcast will be available for 30 days via the
aforementioned URL.
About VAZALOREVAZALORE is an FDA-approved
liquid-filled aspirin capsule, available in 81 mg and 325 mg doses.
VAZALORE delivers aspirin differently from plain and enteric coated
aspirin products. The special complex inside the capsule allows for
targeted release of aspirin, limiting its direct contact with the
stomach. VAZALORE delivers fast, reliable absorption for pain
relief plus the lifesaving benefits of aspirin. To learn more about
VAZALORE, please visit www.vazalore.com.
About PLx Pharma Inc. PLx Pharma,
Inc. is a specialty pharmaceutical company focused on
improving how active pharmaceutical ingredients (APIs) are absorbed
in the gastrointestinal (GI) tract via its clinically validated and
patent protected PLxGuard™ drug delivery platform. PLx believes
this platform has the potential to improve the absorption of many
drugs currently on the market or in development, and to reduce the
risk of stomach injury associated with certain drugs. To learn more
about PLx Pharma Inc. and its pipeline, please
visit www.plxpharma.com.
Contact Investor Relations:Lisa M. Wilson,
In-Site Communications, Inc.T: 212-452-2793E:
lwilson@insitecony.com
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Jun 2024 to Jul 2024
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Jul 2023 to Jul 2024